Boston Scientific taps Meredith to replace Dawkins as CMO
Boston Scientific (NYSE:BSX) said today that it named Ian Meredith to replace Dr. Keith Dawkins as its chief medical officer, effective in January 2017.
“Ian is one of the world’s leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years,” chairman & CEO Mike Mahoney said in prepared remarks. “His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.
“We thank Keith for his many contributions to Boston Scientific during the last nine years. His deep clinical, medical and strategic expertise and advocacy for the patient will have lasting influence within our company,” Mahoney added.
Meredith is a professor of medicine and cardiology at Monash University in Melbourne, Australia, and the principal investigator in the Reprise clinical program for Boston Scientific’s Lotus transcatheter aortic valve replacement.
“Boston Scientific has demonstrated a commitment to delivering meaningful innovation and I look forward to joining the team to further develop the technology pipeline and deliver solutions for patients worldwide,” Meredith said. Read more